1 in 10 Americans Has Used GLP-1 Drugs For Weight Loss, Survey Says
By Dennis Thompson HealthDay Reporter
Medically reviewed by Drugs.com

FRIDAY, Aug. 8, 2025 — More than 1 in 10 Americans have used a GLP-1 drug for weight loss, a new survey by the RAND research group reveals.
About 12% say they’ve tried GLP-1 drugs, like Ozempic, Wegovy or Zepbound, with rates of use highest among people ages 50 to 64, survey results show.
“Of all demographic groups, women between the ages of 50 and 64 had the highest use rate,” wrote the research team led by Robert Bozick, director of RAND Survey Panels. “One in five women, or 20%, reported having ever used GLP-1 agonists.”
Further, many GLP-1 users report side effects like nausea and diarrhea, the survey found.
The report is the most recent and largest survey to date estimating how many Americans have used the revolutionary weight-loss drugs, researchers said.
Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.
Since 2020, prescriptions for GLP-1 drugs have more than tripled, researchers said in background notes.
To see how widespread use has become, RAND surveyed 8,793 Americans in April and May.
Along with the 12% who have tried the drugs, another 14% are interested in giving them a go, the survey found.
Meanwhile, three-quarters of Americans (74%) say they don’t plan to try GLP-1 drugs.
Respondents said the most common side effects associated with GLP-1 drugs were:
“The majority of those who reported having side effects noted that they are mild and not serious,” researchers wrote.
Looking at specific age groups, researchers found that nearly 19% of those 50 to 64 had tried a GLP-1 drug, compared to 13% of those 65 and older and 11% of those 30 to 49.
“Among those 65 and older, use of GLP-1 agonists is somewhat higher for men than for women,” researchers wrote. “Conversely, among those between the ages of 30 and 49, women are more than twice as likely to have used a GLP-1 agonist than their male peers.”
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-08-09 00:00
Read more

- FDA Picks George Tidmarsh to Head Center for Drug Evaluation and Research
- RFK Jr. May Remove Top Panel on Preventive Services Task Force
- EPA Moves to Cancel Key Climate Regulations That Limit Pollution
- Fewer Opioids Being Prescribed for Low Back Pain in the Emergency Department
- FDA Approves Vizz Eye Drops to Improve Near Vision in Adults
- Vaporized Nicotine Products More Effective Than Nicotine Replacement Therapy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions